[The action of decorin in anti-fibrosis and anti-cancer].
Decorin (DCN) is a member of the small leucine-rich proteoglycan gene family. Many studies indicated that DCN inhibited fibrosis and scar-formation by neutralization of TGF-P and interfering the binding of TGF-beta with its receptor, which induced ectopic deposition of extracellular matrix. Additionally, DCN can prevent the proliferation and metastasis of tumor cells by activating EGFR/MAPK/p21 signal pathway and inhibiting the cell proliferation pathway mediated by EGF-EGFR. It is suggested that the recombinant DCN had potential pharmaceutical potency in treatment of chronic fibrosis and neoplasm for its critical biological activities and low immunogenicity.
Ma
Weifeng
W
Key Laboratory for Biomechanics & Tissue Engineering of the State Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400044, China.
Tan
Yi
Y
Cai
Shaohui
S
Chen
Hongyuan
H
Du
Jun
J
Cai
Shaoxi
S
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D058575:Decorin; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D016326:Extracellular Matrix Proteins / Q000737:chemistry* / Q000494:pharmacology*; D005355:Fibrosis / Q000517:prevention & control*; D006801:Humans; D011509:Proteoglycans / Q000737:chemistry* / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000494:pharmacology; D053773:Transforming Growth Factor beta1 / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; C546878:DCN protein, human; D058575:Decorin; D016326:Extracellular Matrix Proteins; D011509:Proteoglycans; D011994:Recombinant Proteins; D053773:Transforming Growth Factor beta1; D066246:ErbB Receptors